<DOC>
	<DOCNO>NCT00101907</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability AMG 706 plus panitumumab administered gemcitabine cisplatin chemotherapy . This Phase 1b clinical study .</brief_summary>
	<brief_title>Safety AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin Treatment Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>For complete inclusion exclusion , please refer investigator . Competent comprehend , sign , date Institutional Review Board ( IRB ) approve informed consent form Subjects advance cancer gemcitabine cisplatin chemotherapy regimen clinically indicate Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematological function Adequate renal function Adequate hepatic function Life expectancy great equal 3 month document investigator More 1 prior chemotherapy regimen History venous thrombosis Myocardial infarction , cerebrovascular accident , transient ischemic attack , percutaneous transluminal coronary angioplasty/stent , unstable angina within 1 year study enrollment History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis screen chest compute tomograph ( CT ) scan Average systolic blood pressure great 145 mm Hg average diastolic blood pressure great 85 mm Hg Radiotherapy within 28 day study enrollment within 14 day study enrollment peripheral lesion Prior AMG 706 , panitumumab , another antiEGFr monoclonal antibody ( mAb ) ( e.g. , cetuximab [ ErbituxÂ® ] EMD 72000 ) Systemic chemotherapy within 28 day study enrollment Major surgery within 28 day minor surgery within 14 day study enrollment Central nervous system metastasis ( Exception : subject treat asymptomatic central nervous system metastasis , clinically stable judgment investigator steroids least 30 day study enrollment eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>AMG 706</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Gemcitabine-Cisplatin</keyword>
</DOC>